Misuse Of Drugs (Amendment) Act 2015

Misuse Of Drugs (Amendment) Act 2015 Skip to content Disclaimer Feedback Helpdesk Gaeilge Léim go dtí an t-ábhar Séanadh Aiseolas Deasc chabhrach English Gaeilge English Produced by the Office of the Attorney General Táirgthe ag Oifig an Ard-Aighne Home Legislation Acts of the Oireachtas Statutory Instruments Pre-1922 Legislation Constitution External Resources Bills (Houses of the Oireachtas) Iris Oifigiúil / Official Gazette Revised Acts (LRC) Classified List of Legislation (LRC) Translations (acts.ie) Translations (Houses of the Oireachtas) Government Publications for Sale EU Law (EUR-Lex) FAQ Disclaimer Feedback Helpdesk Search Baile Reachtaíocht Achtanna an Oireachtais Ionstraimí Reachtúla Reachtaíocht Réamh-1922 Bunreacht Acmhainní Seachtracha Billí (Tithe an Oireachtais) Iris Oifigiúil Achtanna Athbhreithnithe (CAD) (An Coimisiún um Athchóiriú an Dlí) Liosta Rangaithe Reachtaíochta Aistriúcháin (achtanna.ie) Aistriúcháin (Tithe an Oireachtais) Foilseacháin Rialtais ar Díol Dlí AE (EUR-Lex) CCanna (Ceisteanna Coitianta) Séanadh Aiseolas Deasc chabhrach Cuardach TitleTeideal Year(s) or rangeBliain nó blianta nó raon TypeCineál All Legislation Acts Statutory Instruments Advanced SearchCuardach Casta HomeBaile ActsAchtanna 2015 Misuse Of Drugs (Amendment) Act 2015 Misuse Of Drugs (Amendment) Act 2015 Permanent Page URL View by SectionAmharc de réir Ailt View Full ActAmharc ar an Acht Iomlán Bill History Stair Bille Commencement, Amendments, SIs made under the Act Tosach Feidhme, Leasuithe, IRí arna ndéanamh faoin Acht Open PDFOscail PDF Print Full ActPriontáil an tAcht Iomlán Number 6 of 2015 MISUSE OF DRUGS (AMENDMENT) ACT 2015 CONTENTS Section 1. Amendment of Misuse of Drugs Act 1977 2. Confirmation of certain statutory instruments 3. Short title, collective citation, construction and commencement SCHEDULE 1 Insertion of Paragraphs 1A and 1B in Schedule to Misuse of Drugs Act 1977 SCHEDULE 2 Confirmation of Certain Statutory Instruments Acts Referred to Misuse of Drugs Act 1977 (No. 12) Misuse of Drugs Acts 1977 to 2007 Number 6 of 2015 MISUSE OF DRUGS (AMENDMENT) ACT 2015 An Act to amend the Misuse of Drugs Act 1977 ; to confirm certain statutory instruments; and to provide for related matters. [11 th March, 2015] Be it enacted by the Oireachtas as follows: Amendment of Misuse of Drugs Act 1977 1. The Schedule to the Misuse of Drugs Act 1977 is amended— (a) by the insertion, after paragraph 1, of the matter specified in Schedule 1 , (b) by the insertion, in paragraph 2, of “or 1A” after “paragraph 1”, (c) by the insertion of the following paragraph after paragraph 2: “2A. Any stereoisomeric form of a substance specified in paragraph 1B.”, (d) by the insertion, in paragraph 3, of “, 1A” after “paragraph 1”, (e) by the substitution, in paragraph 4, of “paragraph 1, 1A, 1B, 2, 2A or 3” for “paragraph 1, 2 or 3”, and (f) by the substitution, in paragraph 5, of “paragraph 1, 1A, 1B, 2, 2A, 3 or 4” for “paragraph 1, 2, 3 or 4”. Confirmation of certain statutory instruments 2. (1) Every statutory instrument specified in Schedule 2 shall have statutory effect as if it were an Act of the Oireachtas. (2) If subsection (1) would, but for this subsection, conflict with a constitutional right of any person, the operation of that subsection shall be subject to such limitation as is necessary to secure that it does not so conflict but shall otherwise be of full force and effect. Short title, collective citation, construction and commencement 3. (1) This Act may be cited as the Misuse of Drugs (Amendment) Act 2015. (2) This Act and the Misuse of Drugs Acts 1977 to 2007 may be cited together as the Misuse of Drugs Acts 1977 to 2015 and shall be construed together as one Act. (3) This Act shall come into operation on the day immediately following the date of its passing. SCHEDULE 1 Insertion of Paragraphs 1A and 1B in Schedule to Misuse of Drugs Act 1977 Section 1 1A. (a) Alfentanil (3-Amino-2,2-dimethylpropyl)4-aminobenzoate 5-(2-Aminopropyl) indole 1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-pentanone N-(1-Benzyl-4-piperidyl) propionanilide 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl) propan-2-amine Carfentanil Cathinone 3,4-Dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide Dihydroetorphine [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone Dimethocaine 3-Dimethylheptyl-11-hydroxyhexahydrocannabinol Eticyclidine Etryptamine 1-(2-Fluorophenyl)-2-methylaminopropan-1-one 1-(3-Fluorophenyl)-2-methylaminopropan-1-one 1-(4-Fluorophenyl)-2-methylaminopropan-1-one 9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol [9-Hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate N-Hydroxy-tenamphetamine 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine Khat (being the leaves of Catha edulis (Celastraceae)) Lofentanil Methcathinone 2-(3-Methoxyphenyl)-2-(ethylamino)cyclohexanone 1-(4-Methoxyphenyl)-2-(methylamino)propan-1-one Methyl(2S,4aR,6aR,7R,10aS,10bR)-9-acetyloxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]iso-chromene-7-carboxylate and any product, whether natural or otherwise, including any plant or plant material of any kind or description, which contains any proportion of the said substance 2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one 2-Methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one 4-Methyl-aminorex (8-Methyl-8-azabicyclo[3.2.1]octan-3-yl)-4-fluorobenzoate Methyl-2-[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b-hexahydro-1H-indolo[2,3a]quinolizin-2-yl]-3-methoxyprop-2-enoate and any product, whether natural or otherwise, including any plant or plant material of any kind or description, which contains any proportion of the said substance Methyl-2-[(2S,3S,12bS)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b- octahydroindolo[2,3a]quinolizin-2-yl]-3-methoxyprop-2-enoate and any product, whether natural or otherwise, including any plant or plant material of any kind or description, which contains any proportion of the said substance α-Methyl-4-(methylthio)phenethylamine 1-(4-Methylphenyl)-2-methylaminopropan-1-one Nabilone Oripavine Phencyclidine 1-Phenylcyclohexylamine 4-(1-Phenylcyclohexyl)morpholine 1-Piperidinocyclohexanecarbonitrile Remifentanil Rolicyclidine Sufentanil Tapentadol Tenocyclidine N-[1-(2-Thenyl)-4-piperidyl]propionanilide 4-[1-(2-Thienyl)cyclohexyl]morpholine 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine Tilidine. (b) Any substance (not being bupropion) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways: (i) by substitution in the phenyl ring to any extent with alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylenedioxy, haloalkyl or halo substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents; (ii) by substitution at the 2- or 3-position of the propanone side-chain with an alkyl substituent; (iii) by substitution at the nitrogen atom with one or more alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure. (c) Any substance structurally derived from 2-amino-1-propanone by substitution at the 1-position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the substance is further modified in any of the following ways: (i) by substitution in the ring system to any extent with alkyl, alkenyl, alkynyl, alkoxy, alkylthio, haloalkyl or halo substituents, whether or not further substituted in the ring system by one or more other univalent substituents; (ii) by substitution at the 3-position with an alkyl substituent; (iii) by substitution at the 2-amino nitrogen atom with one or more alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure. (d) Any substance structurally derived from 3-(1-benzoyl)indole or 3-(1-naphthoyl)indole by modification in any of the following ways: (i) by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl; (ii) by replacement of one or more hydrogen atoms of any of the substituents referred to in clause (i), with a halo substituent; whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl or naphthyl ring to any extent. (e) 1-Benzylpiperazine or any substance structurally derived from 1-benzylpiperazine or 1-phenylpiperazine by modification in any of the following ways: (i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups; (ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl groups. (f) Any substance structurally derived from fentanyl by modification in one or more of the following ways, that is to say: (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle; (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups; (iii) by substitution in the piperidine ring with alkyl or alkenyl groups; (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups; (v) by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group; (vi) by replacement of the N-propionyl group by another acyl group. (g) Any substance structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent. (h) Any substance structurally derived from 3-(1-naphthoyl)indoleor 1H-indol-3-yl-(1-naphthyl) methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. (i) Any substance structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent. (j) Any substance structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. (k) Any substance structurally derived from pethidine by modification in one or more of the following ways, that is to say: (i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted; (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted; (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups; (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group; (v) by formation of an N-oxide or a quaternary base. (l) Any substance (not being methoxyphenamine) structurally derived from phenethylamine, an N-alkyl-phenethylamine, α-methylphenethylamine, an N-alkyl-α-methylphenethylamine, α-ethylphenethylamine, or an N-alkyl-α-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halo substituents, whether or not further substituted in the ring by one or more other univalent substituents. (m) Any substance structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. (n) Any fungus containing any proportion of psilocin or of an ester of psilocin. (o) 1,2,3,4-Tetrahydronaphthalen-2-amine, 1,2-dihydronaphthalen-2-amine or 2,3-dihydro-1H-inden-2-amine or any substance structurally derived from 1,2,3,4-tetrahydronaphthalen-2-amine, 1,2-dihydronaphthalen-2-amine or 2,3-dihydro-1H-inden-2-amine by modification in any of the following ways: (i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkenyl, alkynyl, alkylthio, alkylenedioxy, haloalkyl, hydroxy or halo substituents, whether or not further substituted by one or more other univalent substituents; (ii) by mono - or di-substitution at the nitrogen atom with alkyl, alkenyl, alkynyl or haloalkyl groups or by inclusion of the nitrogen atom in a cyclic structure. (p) Any substance structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the side-chain with one or more alkyl substituents but no other substituent. 1B. (a) Alprazolam Amineptine Aminorex Amphetaminil 2-Benzhydrylpiperidine Bromazepam Brotizolam Buprenorphine Butan-1,4-diol Butorphanol Camazepam Cathine Chlordiazepoxide Clobazam Clonazepam Clorazepic acid Clotiazepam Cloxazolam Delorazepam Dextropropoxyphene Diazepam Diethylpropion Dihydrofuran-2(3H)-one Estazolam Ethchlorvnol Ethinamate N-Ethylamphetamine Ethyl loflazepate Fencamfamin Fenethylline Fenproporex Fludiazepam Flunitrazepam Flurazepam Glutethimide Halazepam Haloxazolam 4-Hydroxybutanoic acid Ketamine Ketazolam Lefetamine Loprazolam Lorazepam Lormetazepam Mazindol Mecloqualone Medazepam Mefenorex Meprobamate Mesocarb Methyprylone Midazolam Nalbuphine Nimetazepam Nitrazepam Nordazepam Oxazepam Oxazolam Pemoline Pentazocine Phentermine Pinazepam Prazepam Propylhexedrine Pyrovalerone Selegiline Temazepam Tetrazepam Triazolam Zipeprol Zolpidem. (b) Any substance structurally derived from barbituric acid by di-substitution at the 5-position, whether or not there is also substitution at the 1-position by a methyl substituent. SCHEDULE 2 Confirmation of Certain Statutory Instruments Section 2 Number & Year Title of Instrument No. 164 of 1979 Misuse of Drugs (Licence Fees) Regulations 1979 No. 321 of 1982 Misuse of Drugs (Safe Custody) Regulations 1982 No. 326 of 1988 Misuse of Drugs (Exemption) Order 1988 No. 328 of 1988 Misuse of Drugs Regulations 1988 No. 69 of 1998 Misuse of Drugs (Designation) Order 1998 No. 225 of 1998 Misuse of Drugs (Supervision of Prescription and Supply of Methadone) Regulations 1998 Privacy Statement Accessibility European Legislation Identifier (PDF) Open Data License Ráiteas Príobháideachais Inrochtaineacht Aitheantóir Eorpach Reachtaíochta (ELI) Ceadúnas Sonraí Oscailte Liosta Fianán © Government of Ireland. Oireachtas Copyright Material is reproduced with the permission of the Houses of the Oireachtas © Rialtas na hÉireann. Atáirgtear ábhar faoi Chóipcheart le cead ó Thithe an Oireachtais